Geriatric populations (≥ 75 years) have been underrepresented in clinical trials evaluating the renoprotective effects of SGLT2 inhibitors, resulting in limited data on their efficacy in elderly DKD patients. The gene discussed is SLC5A2; the disease is diabetic kidney disease.